EMBC · Embecta Corp.

Track EMBC — free

$5.05 +0.08 (+1.61%)

Russell 2000 member Rebalance outlook locked

Market Cap

$281.60M

56.66M

Up next

Next earnings call

Nov 7, 2026 Est · unconfirmed · in 10 wks

FQ4-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed Aug 7, 2026

AI Brief

TL;DR.

Bullish

Bearish

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Ask ALVIS about this →

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Neutral Momentum Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High

Market backdrop VIX 14.5 · calm Equity put/call 0.39

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg −38%

below

Price vs 50-day avg +29%

above

RSI (14) 61

neutral

MACD trend Negative

52-week position 17%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Weak

1-month return +36%

trailing

6-month return −45%

trailing

YTD return −58%

this year

Relative strength −60%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $4 › 200d $8 — 200d above 50d

Institutional flow Distributing

-7% holders QoQ · +65 funds added

Insider flow Accumulating

Net +$557.9K over 90 days · 0% sells

Short interest Falling

9.61% of float · ▼ -18.5% MoM · 2.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr low

319 holders — near 3-yr low, contrarian setup

Squeeze score 64

elevated · 0–100

Fundamentals

Strong

Revenue growth −4%

Y/Y

Gross margin 63%

contracting

EPS growth +21%

Y/Y

Free cash flow $182.4M

Valuation P/E 3.4

below peers

Buyback $100.0M

authorized

Balance sheet $1.2B

net debt

Quant / Vol

risk profile

Very High

Volatility 80%

annualized · 1-yr

Max drawdown −81%

past year

ATR 5.7%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the Earnings Call filed Jun 30, 2026

fiscal year 2026

Revenue Initiated $1.02B – $1.04B

prior FY $1.08B midpoint −5.1% Y/Y

2026

Adjusted operating margin Non-GAAP 23.5% – 24%

Adjusted tax rate Non-GAAP 27%

Adjusted Earnings Per Share Non-GAAP $1.80 – $1.90

Debt repayment at least $150M

Interest expense $95M

Free cash flow $100M

FX impact on revenue 1.3%

Prior guidance period ended · from the 8-K filed Aug 8, 2025

Adjusted Constant Currency Revenue Growth (%) · fiscal year 2025 -3.6% – -3%

Guided vs delivered · last 1 settled

As reported revenue full-year 2023

guided $1.11B – $1.11B

guided $1.11B – $1.11B $1.12B Beat +1.0%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral

2 · 4 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−38% Bearish

Price vs 50-day avg

+29% Bullish

RSI (14)

61 Neutral

MACD trend

Negative Bearish

52-week position

17% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $4 › 200d $8 — 200d above 50d

Institutional flow Distributing

-7% holders QoQ · +65 funds added

Insider flow Accumulating

Net +$557.9K over 90 days · 0% sells

Short interest Falling

9.61% of float · ▼ -18.5% MoM · 2.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr low

319 holders — near 3-yr low, contrarian setup

Price context

position in its 52-week range

Range low $3 Now $5 · 17% Range high $15

vs 200-day avg -38% vs 50-day avg +29%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Adjusted earnings per diluted share non-GAAP	$1.53	Nine months ended June 30, 2026	—

Adjusted EBITDA non-GAAP	$247.5M	nine months ended June 30, 2026	—

Adjusted EBITDA and margin non-GAAP	$247.5M	Nine months ended June 30, 2026	—

Adjusted EBITDA margin non-GAAP	32.8%	Nine months ended June 30, 2026	—

Adjusted Gross Profit non-GAAP	$158M	Three Months Ended June 30	—

Adjusted gross profit and margin non-GAAP	58.2%	Three months ended June 30, 2026	—

Adjusted Gross Profit Margin non-GAAP	58.2%	Three Months Ended June 30	—

Adjusted Net Income non-GAAP	$32.6M	Three Months Ended June 30	—

Adjusted net income and adjusted earnings per diluted share non-GAAP	$91M	Nine months ended June 30, 2026	—

Adjusted Operating Income non-GAAP	$69.4M	Three Months Ended June 30	—

Adjusted operating income and margin non-GAAP	25.5%	Three months ended June 30, 2026	—

Adjusted Operating Income Margin non-GAAP	25.5%	Three Months Ended June 30	—

Non-GAAP Free Cash Flow non-GAAP	$40.7M	Three Months Ended June 30	—

GAAP → non-GAAP reconciliation GAAP Net Cash Provided by Operating Activities 41.8M -1.1M Capital expenditures = Non-GAAP Free Cash Flow 40.7M
Adjusted Revenues non-GAAP	$483M	Six Months Ended March 31, 2026	—
embecta revenue represented by products commercially launched and shipped under the embecta labe	75%	Second Quarter Fiscal Year 2026	—
Identified partners either in contract negotiations or having executed agreements	40%	Second Quarter Fiscal Year 2026	—
Adjusted constant currency revenue growth non-GAAP	2%	Q1 FY2026	—
Adjusted gross margin non-GAAP	62.6%	Q1 FY2026	—
Adjusted operating margin non-GAAP	30.4%	Q1 FY2026	—
Dividend per share	$0.15	Q1 FY2026	—
International revenue growth (adjusted constant currency) non-GAAP	4.6%	Q1 FY2026	—
U.S. revenue growth (reported and adjusted constant currency) non-GAAP	7.6%	Q1 FY2026	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Instruments & Supplies — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
EMBC Embecta Corp. this stock	$281.60M	-58.2%	-3.8%	3.4	9.6%
ISRG Intuitive Surgical Inc	$129.68B	-35.2%	+20.5%	42.1	2.0%
BDX Becton Dickinson & Co	$51.81B	—	+8.2%	—	3.4%
MDLN Medline Inc.	$45.55B	-17.5%	+11.5%	—	2.8%
ALC Alcon Inc	$35.13B	-8.3%	+10.5%	—	2.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

319

% held: 88.9%
Net QoQ: -10.5M sh
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

226

View

Short & Settlement

Short Interest Falling

Shares short

5.4M

Days to cover: 2.5d
Change: -1.2M sh

View

Short Volume

Short vol %

45%

As of: Aug 28, 2026

Short Total

View

Fails to Deliver

FTD shares

15.9K

Value: $52.2K
As of: Jul 27, 2026

View

Off-Exchange

Off-exchange %

27.5%

Week of: Jul 20, 2026

Off-exch Lit

View

Smart Money

Insider Trades Cluster buy

Net (90d)

+$557.9K

Buyers / Sellers: 4 / 0

Buyers Sellers

View

Financials

Revenue (FY)

$1.1B

Net income (FY): $95.4M
EPS diluted: $1.62

View

Buybacks

Authorized

$100.0M

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 7, 2026
This year: 10

View

Proposed Sales

Value

$50.8K

Shares: 3.1K
Filed: Feb 13, 2025

View

Earnings & Events

Earnings Calls

Last call

Aug 7, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
EMBC	-9.1%	+35.8%	-45.2%	+36.5%	-58.2%
SPY	+1.1%	+4.0%	+14.7%	+3.2%	+13.1%
vs SPY	-10.3%	+31.8%	-59.9%	+33.3%	-71.2%

Capital returns

Latest dividend

$0.01 / share · ex Aug 27, 2026

Cut 93.3%

Paid (TTM)

$0.47 / share · 5 payouts

Dividend yield (TTM, derived)

9.46%

Buyback program · as of Aug 7, 2026

Authorized

$100.00M

Spent (derived)

—

Remaining

—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1872789 CUSIP 29082K105 13F (30d) 239 filings 239 filers Visit website Investor relations

EMBC · Embecta Corp.

Price & Indicators

Up next

AI Brief

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance

Capital returns